Stay Connected

sign up for news or event

Research and Development Services

Doppel has its own dedicated R&D division staffed by highly qualified scientific experts and equipped with a range of advanced technologies to perform independent R&D activities

Trilantic Capital Partners Europe Completes Acquisition

Trilantic Capital Partners Europe (“Trilantic Europe”), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici (“Doppel” or the “Company”), after obtaining anti-trust approvals. Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging.

+ read more